Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease
Research from the University of Oxford found that those who stop regain weight steadily, returning close to their original size within approximately 1.7 years [BMJ, 2026]
So now we're basing optimal lab ranges on people who are ill, which is never okay
GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history
The lipotropic consists of the following: Methionine: helps break down sugars & carbohydrates and convert to energy Inositol: Converts food to energy Choline: Healthy nerve cells, cuts muscle recovery time, helps convert fat to energy Pyridoxine: Promotes red blood cell production plus converts food to energy Cyanocobalamin: Energy, healthy nerve cells Recommend Dose Intramuscular (IM) 1ml/weekly
GHK-Cu topical products do not need to be reconstituted
